1
|
Quintela-Fandino M, Manso Sànchez L, Holgado Martín E, Moreno M, Morales Murillo S, Bermejo De Las Heras B, Malon Gimenez D, Colomer Bosch R, Gonzalez Cortijo L, Hornedo J, Mouron S, Muñoz M, Escudero S, Blanco R, Mañes S. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy430.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Perez-Villamil B, Paz-Cabezas M, Calvo-López T, Ogando-Castro J, Sastre J, Mañes S, Díaz-Rubio E. microRNA(miR) subtypes correlates with colorectal cancer(CRC) molecular subtypes: Validation of miR-30b interaction with genes up-regulated in the high-stroma subtype. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Quintela-Fandino M, Manso L, Mouron S, Lopez-Acosta JF, García-Saenz JA, Holgado E, Pascual-Martinez T, Medicna L, Guerra J, Gonzalez-Cortijo L, Mañes S. Abstract OT3-01-02: CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The role of immune checkpoints in tumor progression is less relevant in breast cancer than in other malignancies. However, in preclinical experimentation we found a niche for immune checkpoint inhibitors. In an immunocompetent model of HER2-negative breast cancer (MMTV-PyMT) we observed that antiangiogenic agents may induce either a tumor normoxic or hypoxic adaptation. Normoxic adaptation leads to a therapeutically exploitable dependence on mitochondrial metabolism (Cell Rep 2016; 15: 1-14). Hypoxic adaptation (usually caused by monoclonal antibody type antiangiogenics) induces an increase in PGE2 and PGA synthesis, followed by a switch of the tryptophan metabolism from 5HIAA to kinurenine that culminates in differentiation of naive T-cells to Tregs and expression of PD-L1 in the hypoxic areas. The exhausted T-cell response observed in this model can be restored with PD-L1 inhibitors. We sought to prove the relevance of T-cell exhaustion an its reversibility by the anti-PD-L1 antibody durvalumab in patients receiving chronic bevacizumab (Bev).
Trial design
Single-arm, prospective, multicentric, phase II open-label trial. Patients receiving Bev maintenance after a chemotherapy+Bev regimen administered in the first line of metastatic disease that experience disease progression (PD) during maintenance will be candidates. The treatment will start by adding durvalumab (10 mg/kg q2w) to the ongoing Bev (15 mg/kg q3 w). Patients will undergo serial tumor biopsies, tumor-cfDNA sequencing (baseline and progression), and immunophenotyping (baseline and q4w). RECIST/I-RECIST and NCI CTC AE V4.03 criteria will be used for assessing disease response and toxicity.
Elegibility criteria
Women >18 year old diagnosed of HER2-negative advanced breast cancer; 2) have received chemotherapy plus Bev for the first line treatment and experienced PR, CR or SD, 3) followed by maintenance with three-weekly Bev in monotherapy for at least 6 weeks before diagnosis of PD. 4) Concurrent hormonal therapy is allowed for ER+ patients, but reception of previous immunotherapy is precluded. 5) Adequate organ function defined according to standard parameters.
Specific aims
Primary:
1) To determine the relative percentages of innate and adaptive immune cell subpopulations and ascertain the status of T-cell function and polarization by multiparametric flow cytometry in patients with acquired resistance against Bev
2) To assess the reversibility of the abnormalities evidenced in (1) by durvalumab
3) To determine the disease control rate of the combination, and its relationship with (1) and (2)
Secondary:
4) To determine potential tumor neoantigens generated by chronic tumor hypoxia secondary to the antiangiogenic treatment.
Statistical methods
The sample size is calculated on the basis of the expected change in the Treg percentage in peripheral blood (10%), with an alpha and beta errors of 5% and 20% respectively. The minimum number of patients necessary to observe a 10% decrease is 25. Changes in lymphocytes will be compared with intra-subject measurements and Z-scores.
Accrual: 2 of 25 (target accrual) patients have been recruited.
Contact info: mquintela@cnio.es.
Citation Format: Quintela-Fandino M, Manso L, Mouron S, Lopez-Acosta JF, García-Saenz JA, Holgado E, Pascual-Martinez T, Medicna L, Guerra J, Gonzalez-Cortijo L, Mañes S. CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-01-02.
Collapse
Affiliation(s)
- M Quintela-Fandino
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - L Manso
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - S Mouron
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - JF Lopez-Acosta
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - JA García-Saenz
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - E Holgado
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - T Pascual-Martinez
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - L Medicna
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - J Guerra
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - L Gonzalez-Cortijo
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| | - S Mañes
- CNIO - Spanish National Cancer Research Center, Madrid, Spain; H12O -Hospital 12 de Octubre, Madrid, Spain; HSCC - Hospital Clinico San Carlos, Madrid, Spain; HRYC - Hospital Ramon y Cajal, Madrid, Spain; HLP - Hospital La Princesa, Madrid, Spain; HUF - Hospital Universitario Fuenlabrada, Madrid, Spain; HQ - Hospital Quiron, Madrid, Spain; CNB - Centro Nacional de Biotecnología, Madrid, Spain
| |
Collapse
|
4
|
Lacalle RA, Blanco R, Carmona-Rodríguez L, Martín-Leal A, Mira E, Mañes S. Chemokine Receptor Signaling and the Hallmarks of Cancer. Int Rev Cell Mol Biol 2016; 331:181-244. [PMID: 28325212 DOI: 10.1016/bs.ircmb.2016.09.011] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The chemokines are a family of chemotactic cytokines that mediate their activity by acting on seven-transmembrane-spanning G protein-coupled receptors. Both the ability of the chemokines and their receptors to form homo- and heterodimers and the promiscuity of the chemokine-chemokine receptor interaction endow this protein family with enormous signaling plasticity and complexity that are not fully understood at present. Chemokines were initially identified as essential regulators of homeostatic and inflammatory trafficking of innate and adaptive leucocytes from lymphoid organs to tissues. Chemokines also mediate the host response to cancer. Nevertheless, chemokine function in this response is not limited to regulating leucocyte infiltration into the tumor microenvironment. It is now known that chemokines and their receptors influence most-if not all-hallmark processes of cancer; they act on both neoplastic and untransformed cells in the tumor microenvironment, including fibroblasts, endothelial cells (blood and lymphatic), bone marrow-derived stem cells, and, obviously, infiltrating leucocytes. This review begins with an overview of chemokine and chemokine receptor structure, to better define how chemokines affect the proliferation, survival, stemness, and metastatic potential of neoplastic cells. We also examine the main mechanisms by which chemokines regulate tumor angiogenesis and immune cell infiltration, emphasizing the pro- and antitumorigenic activity of this protein superfamily in these interrelated processes.
Collapse
Affiliation(s)
- R A Lacalle
- Centro Nacional de Biotecnología/CSIC, Madrid, Spain
| | - R Blanco
- Centro Nacional de Biotecnología/CSIC, Madrid, Spain
| | | | - A Martín-Leal
- Centro Nacional de Biotecnología/CSIC, Madrid, Spain
| | - E Mira
- Centro Nacional de Biotecnología/CSIC, Madrid, Spain
| | - S Mañes
- Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
| |
Collapse
|
5
|
Labrador JP, Azcoitia V, Tuckermann J, Lin C, Olaso E, Mañes S, Brückner K, Goergen JL, Lemke G, Yancopoulos G, Angel P, Martínez C, Klein R. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Rep 2001; 2:446-52. [PMID: 11375938 PMCID: PMC1083888 DOI: 10.1093/embo-reports/kve094] [Citation(s) in RCA: 189] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The discoidin domain receptor 2 (DDR2) is a member of a subfamily of receptor tyrosine kinases whose ligands are fibrillar collagens, and is widely expressed in postnatal tissues. We have generated DDR2-deficient mice to establish the in vivo functions of this receptor, which have remained obscure. These mice exhibit dwarfism and shortening of long bones. This phenotype appears to be caused by reduced chondrocyte proliferation, rather than aberrant differentiation or function. In a skin wound healing model, DDR2-/- mice exhibit a reduced proliferative response compared with wild-type littermates. In vitro, fibroblasts derived from DDR2-/- mutants proliferate more slowly than wild-type fibroblasts, a defect that is rescued by introduction of wild-type but not kinase-dead DDR2 receptor. Together our results suggest that DDR2 acts as an extracellular matrix sensor to modulate cell proliferation.
Collapse
Affiliation(s)
- J P Labrador
- European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Gómez-Móuton C, Abad JL, Mira E, Lacalle RA, Gallardo E, Jiménez-Baranda S, Illa I, Bernad A, Mañes S, Martínez-A C. Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization. Proc Natl Acad Sci U S A 2001; 98:9642-7. [PMID: 11493690 PMCID: PMC55505 DOI: 10.1073/pnas.171160298] [Citation(s) in RCA: 408] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2001] [Indexed: 11/18/2022] Open
Abstract
Redistribution of specialized molecules in migrating cells develops asymmetry between two opposite cell poles, the leading edge and the uropod. We show that acquisition of a motile phenotype in T lymphocytes results in the asymmetric redistribution of ganglioside GM3- and GM1-enriched raft domains to the leading edge and to the uropod, respectively. This segregation to each cell pole parallels the specific redistribution of membrane proteins associated to each raft subfraction. Our data suggest that raft partitioning is a major determinant for protein redistribution in polarized T cells, as ectopic expression of raft-associated proteins results in their asymmetric redistribution, whereas non-raft-partitioned mutants of these proteins are distributed homogeneously in the polarized cell membrane. Both acquisition of a migratory phenotype and SDF-1alpha-induced chemotaxis are cholesterol depletion-sensitive. Finally, GM3 and GM1 raft redistribution requires an intact actin cytoskeleton, but is insensitive to microtubule disruption. We propose that membrane protein segregation not only between raft and nonraft domains but also between distinct raft subdomains may be an organizational principle that mediates redistribution of specialized molecules needed for T cell migration.
Collapse
Affiliation(s)
- C Gómez-Móuton
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Cantoblanco, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Mellado M, Rodríguez-Frade JM, Mañes S, Martínez-A C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 2001; 19:397-421. [PMID: 11244042 DOI: 10.1146/annurev.immunol.19.1.397] [Citation(s) in RCA: 288] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A broad array of biological responses, including cell polarization, movement, immune and inflammatory responses, and prevention of HIV-1 infection, are triggered by the chemokines, a family of structurally related chemoattractant proteins that bind to specific seven-transmembrane receptors linked to G proteins. Here we discuss one of the early signaling pathways activated by chemokines, the JAK/STAT pathway. Through this pathway, and possibly in conjunction with other signaling pathways, the chemokines promote changes in cellular morphology, collectively known as polarization, required for chemotactic responses. The polarized cell expresses the chemokine receptors at the leading cell edge, to which they are conveyed by rafts, a cholesterol-enriched membrane fraction fundamental to the lateral organization of the plasma membrane. Finally, the mechanisms through which the chemokines promote their effect are discussed in the context of the prevention of HIV-1 infection.
Collapse
Affiliation(s)
- M Mellado
- Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, UAM Campus de Cantoblanco, Madrid, E-28049 Spain
| | | | | | | |
Collapse
|
8
|
Abstract
Cell chemotaxis requires the acquisition and maintenance of both spatial and functional asymmetry between initially equivalent cell parts. In leukocytes one becomes the leading edge and the other, the rear edge or uropod. The acquisition of this cell polarity is controlled by an array of chemoattractants, including those of the chemokine family. We propose that chemokine receptor activation in highly organized lipid raft domains is a major determinant for the correct localization of the signaling pathways leading to the cell asymmetries required for migration. The lateral organization imposed by membrane raft microdomains is discussed in the context of other chemokine receptor activities, such as its role as a human immunodeficiency virus (HIV) coreceptor.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Campus de Cantoblanco, E-28049, Spain.
| | | | | | | | | | | |
Collapse
|
9
|
Mira E, Lacalle RA, González MA, Gómez-Moutón C, Abad JL, Bernad A, Martínez-A C, Mañes S. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep 2001; 2:151-6. [PMID: 11258708 PMCID: PMC1083823 DOI: 10.1093/embo-reports/kve027] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Complex cell responses require the integration of signals delivered through different pathways. We show that insulin-like growth factor (IGF)-I induces specific transactivation of the Gi-coupled chemokine receptor CCR5, triggering its tyrosine phosphorylation and Galpha recruitment. This transactivation occurs via a mechanism involving transcriptional upregulation and secretion of RANTES, the natural CCR5 ligand. CCR5 transactivation is an essential downstream signal in IGF-I-induced cell chemotaxis, as abrogation of CCR5 function with a transdominant-negative KDELccr5A32 mutant abolishes IGF-I-induced migration. The relevance of this transactivation pathway was shown in vivo, as KDELccr5A32 overexpression prevents invasion by highly metastatic tumor cells; conversely, RANTES overexpression confers built-in invasive capacity on a non-invasive tumor cell line. Our results suggest that this extracellular growth factor-chemokine network represents a general mechanism connecting tumorigenesis and inflammation.
Collapse
Affiliation(s)
- E Mira
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Cientificias, Universidad Autónoma de Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Mañes S, del Real G, Lacalle RA, Lucas P, Gómez-Moutón C, Sánchez-Palomino S, Delgado R, Alcamí J, Mira E, Martínez-A C. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000; 1:190-6. [PMID: 11265761 PMCID: PMC1084257 DOI: 10.1093/embo-reports/kvd025] [Citation(s) in RCA: 290] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2000] [Revised: 06/06/2000] [Accepted: 06/21/2000] [Indexed: 11/12/2022] Open
Abstract
HIV-1 infection triggers lateral membrane diffusion following interaction of the viral envelope with cell surface receptors. We show that these membrane changes are necessary for infection, as initial gp120-CD4 engagement leads to redistribution and clustering of membrane microdomains, enabling subsequent interaction of this complex with HIV-1 co-receptors. Disruption of cell membrane rafts by cholesterol depletion before viral exposure inhibits entry by both X4 and R5 strains of HIV-1, although viral replication in infected cells is unaffected by this treatment. This inhibitory effect is fully reversed by cholesterol replenishment of the cell membrane. These results indicate a general mechanism for HIV-1 envelope glycoprotein-mediated fusion by reorganization of membrane microdomains in the target cell, and offer new strategies for preventing HIV-1 infection.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Throughout evolution, both prokaryotic and eukaryotic cells have developed a variety of biochemical mechanisms to define the direction and proximity of extracellular stimuli. This process is essential for the cell to reply properly to the environmental cues that determine cell migration, proliferation, and differentiation. Chemotaxis is the cellular response to chemical attractants that direct cell migration, a process that plays a central role in many physiological situations, such as host immune responses, angiogenesis, wound healing, embryogenesis, and neuronal patterning, among others. In addition, cell migration takes part in pathological states, including inflammation and tumor metastasis. Indeed, tumor progression to invasion and metastasis depends on the active motility of the invading cancer cells and the endothelial cell bed during tumor neovascularization. Cell migration switches "off" and "on," based on quantitative differences in molecular components such as adhesion receptors, cytoskeletal linking proteins, and extracellular matrix ligands, and by regulating the affinity of membrane-bound chemoattractant receptors. A clear understanding of how cells sense chemoattractants is, therefore, of pivotal importance in the biology of the normal cell as well as in prevention of malignant cell invasion. Here we offer a perspective on cell migration that emphasizes the relationship between cell polarization and cell movement and the importance of the equilibrium between the signals that drive each process for the control of tumor cell invasion.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Universidad Autónoma de Madrid/Campus de Cantoblanco, Spain
| | | | | | | | | |
Collapse
|
12
|
Mañes S, Mira E, Gómez-Moutón C, Lacalle RA, Keller P, Labrador JP, Martínez-A C. Membrane raft microdomains mediate front-rear polarity in migrating cells. EMBO J 1999; 18:6211-20. [PMID: 10562533 PMCID: PMC1171684 DOI: 10.1093/emboj/18.22.6211] [Citation(s) in RCA: 262] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The acquisition of spatial and functional asymmetry between the rear and the front of the cell is a necessary step for cell chemotaxis. Insulin-like growth factor-I (IGF-I) stimulation of the human adenocarcinoma MCF-7 induces a polarized phenotype characterized by asymmetrical CCR5 chemokine receptor redistribution to the leading cell edge. CCR5 associates with membrane raft microdomains, and its polarization parallels redistribution of raft molecules, including the raft-associated ganglioside GM1, glycosylphosphatidylinositol-anchored green fluorescent protein and ephrinB1, to the leading edge. The non-raft proteins transferrin receptor and a mutant ephrinB1 are distributed homogeneously in migrating MCF-7 cells, supporting the raft localization requirement for polarization. IGF-I stimulation of cholesterol-depleted cells induces projection of multiple pseudopodia over the entire cell periphery, indicating that raft disruption specifically affects the acquisition of cell polarity, but not IGF-I-induced protrusion activity. Cholesterol depletion inhibits MCF-7 chemotaxis, which is restored by replenishing cholesterol. Our results indicate that initial segregation between raft and non-raft membrane proteins mediates the necessary redistribution of specialized molecules for cell migration.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Campus de Cantoblanco, E-28049 Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
13
|
Llorente M, Sánchez-Palomino S, Mañes S, Lucas P, Kremer L, De Alborán IM, Torán JL, Alcamí J, Del Real G, Martínez-A C. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Scand J Immunol 1999; 50:270-9. [PMID: 10447936 DOI: 10.1046/j.1365-3083.1999.00516.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We have characterized the human natural antibody repertoire that contains antibodies recognizing the human immunodeficiency virus type 1 (HIV-1) gp120. A panel of monovalent antigen-binding fragments (Fab) selected from IgM and IgG isotype libraries generated from peripheral blood mononuclear cells (PBMC) of a healthy, HIV-1 noninfected individual was analysed, reflecting that only IgM, but not IgG, Fab were able to recognize HIV-1 gp120. The IgM Fab antibodies were not restricted to any particular heavy chain variable region (VH) germ line gene. However, the recognition of gp120 is associated to polyreactive antibodies and all display low-affinity interaction. This correlates with the absence of any maturation process as somatic mutation or isotype switch as the nucleotide sequence analysis of the variable regions reveals they are expressed near to germline configuration. In addition, none of the antibodies showed any neutralizing activity on HIV-1-infected lymphocytes, reflecting that the natural anti-gp120 repertoire is not sufficient to neutralize HIV infection.
Collapse
Affiliation(s)
- M Llorente
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC/UAM, Campus de Cantoblanco, E-28049, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Mira E, Mañes S, Lacalle RA, Márquez G, Martínez-A C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999; 140:1657-64. [PMID: 10098500 DOI: 10.1210/endo.140.4.6623] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
MCF-7 cells migrate through vitronectin-coated filters in response to insulin-like growth factor I (IGF-I); migration is inhibited by the matrix metalloproteinase (MMP) inhibitor BB-94, but not by the serine proteinase inhibitor aprotinin. MMP-9 was identified in the conditioned medium of MCF-7 cells; in addition, fluorescence-activated cell sorting analysis revealed its presence on the cell surface, where MMP-9 activity was also found using a specific fluorogenic peptide. Furthermore, the messenger RNA encoding MMP-9 was detected in MCF-7 cells by PCR. The IGF-I concentration leading to maximal MCF-7 invasion produces an increase in cell surface proteolytic activity after short incubation periods. At 18 h, however, preincubation of MCF-7 cells with IGF-I produces at 18 h a dose-dependent decrease in cell-associated MMP-9 activity and an increase in soluble MMP-9. MCF-7 invasion is dependent on the alpha(v)beta5 integrin, a vitronectin receptor. The levels of alpha(v)- and beta5-subunits expressed in MCF-7 cells depend on the IGF-I concentration, which triggers an increase in both of these subunits. Based on these results, we suggest that IGF-I-induced MCF-7 cell migration is mediated by the MMP-9 activity on the cell surface and by alpha(v)beta5 integrin.
Collapse
Affiliation(s)
- E Mira
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Spain.
| | | | | | | | | |
Collapse
|
15
|
Mañes S, Mira E, Gómez-Mouton C, Zhao ZJ, Lacalle RA, Martínez-A C. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol 1999; 19:3125-35. [PMID: 10082579 PMCID: PMC84106 DOI: 10.1128/mcb.19.4.3125] [Citation(s) in RCA: 203] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
The coordinated interplay of substrate adhesion and deadhesion is necessary for cell motility. Using MCF-7 cells, we found that insulin-like growth factor I (IGF-I) induces the adhesion of MCF-7 to vitronectin and collagen in a dose- and time-dependent manner, suggesting that IGF-I triggers the activation of different integrins. On the other hand, IGF-I promotes the association of insulin receptor substrate 1 with the focal adhesion kinase (FAK), paxillin, and the tyrosine phosphatase SHP-2, resulting in FAK and paxillin dephosphorylation. Abrogation of SHP-2 catalytic activity with a dominant-negative mutant (SHP2-C>S) abolishes IGF-I-induced FAK dephosphorylation, and cells expressing SHP2-C>S show reduced IGF-I-stimulated chemotaxis compared with either mock- or SHP-2 wild-type-transfected cells. This impairment of cell migration is recovered by reintroduction of a catalytically active SHP-2. Interestingly, SHP-2-C>S cells show a larger number of focal adhesion contacts than wild-type cells, suggesting that SHP-2 activity participates in the integrin deactivation process. Although SHP-2 regulates mitogen-activated protein kinase activity, the mitogen-activated protein kinase kinase inhibitor PD-98059 has only a marginal effect on MCF-7 cell migration. The role of SHP-2 as a general regulator of cell chemotaxis induced by other chemotactic agents and integrins is discussed.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Campus de Cantoblanco, E-28049 Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
16
|
Mañes S, Llorente M, Lacalle RA, Gómez-Moutón C, Kremer L, Mira E, Martínez-A C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 1999; 274:6935-45. [PMID: 10066747 DOI: 10.1074/jbc.274.11.6935] [Citation(s) in RCA: 153] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The androgen-independent human prostate adenocarcinoma cell line DU-145 proliferates in serum-free medium and produces insulin-like growth factors (IGF)-I, IGF-II, and the IGF type-1 receptor (IGF-1R). They also secrete three IGF-binding proteins (IGFBP), IGFBP-2, -3, and -4. Of these, immunoblot analysis revealed selective proteolysis of IGFBP-3, yielding fragments of 31 and 19 kDa. By using an anti-IGF-I-specific monoclonal antibody (mAb), we detect surface receptor-bound IGF-I on serum-starved DU-145 cells, which activates IGF-1R and triggers a mitogenic signal. Incubation of DU-145 cells with blocking anti-IGF-I, anti-IGF-II, or anti-IGF-I plus anti-IGF-II mAb does not, however, inhibit serum-free growth of DU-145. Conversely, anti-IGF-1R mAb and IGFBP-3 inhibit DNA synthesis. IGFBP-3 also modifies the DU-145 cell cycle, decreases p34(cdc2) levels, and IGF-1R autophosphorylation. The antiproliferative IGFBP-3 activity is not IGF-independent, since des-(1-3)IGF-I, which does not bind to IGFBP-3, reverses its inhibitory effect. DU-145 also secretes the matrix metalloproteinase (MMP)-9, which can be detected in both a soluble and a membrane-bound form. Matrix metalloproteinase inhibitors, but not serpins, abrogate DNA synthesis in DU-145 associated with the blocking of IGFBP-3 proteolysis. Overexpression of an antisense cDNA for MMP-9 inhibits 80% of DU-145 cell proliferation that can be reversed by IGF-I in a dose-dependent manner. Inhibition of MMP-9 expression is also associated with a decrease in IGFBP-3 proteolysis and with reduced signaling through the IGF-1R. Our data indicate an IGF autocrine loop operating in DU-145 cells, specifically modulated by IGFBP-3, whose activity may in turn be regulated by IGFBP-3 proteases such as MMP-9.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Campus de Cantoblanco, E-28049 Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
17
|
Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-A C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997; 272:25706-12. [PMID: 9325295 DOI: 10.1074/jbc.272.41.25706] [Citation(s) in RCA: 166] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
To elucidate the physiological role of human stromelysin-3 (hST-3) in tumor progression and/or wound healing, insulin-like growth factor-binding protein-1 (IGFBP-1) was analyzed as a potential physiological substrate. hST-3 proteolysis generates two fragments of 16 and 9 kDa that react with IGFBP-1 monoclonal antibody, although they do not bind insulin-like growth factor-I (IGF-I) in ligand blot. N-terminal sequencing shows that hST-3 cleaves IGFBP-1 at the His140-Val141 bond located in the IGFBP-1 midregion. We show that IGFBP-1 inhibits IGF-I-induced survival and proliferation of BAF/3 cells, as well as IGF-I-mediated activation of phosphatidylinositol 3-kinase (PI 3-K). Co-incubation of the IGF-I. IGFBP-1 complex with hST-3 restores IGF-I-induced proliferation and PI 3-K kinase activity in these cells. BAF/3 proliferation is significantly increased with the hST-3-treated IGF-I.IGFBP-1 complex compared with that obtained using IGF-I alone. To produce this enhanced proliferation, IGF-I must bind to IGFBP-1 before hST-3 proteolysis, demonstrated using an IGF-I variant that does not bind IGFBP. IGFBP-1 also inhibits IGF-I-induced proliferation of the MCF-7 breast adenocarcinoma, and this inhibition was not seen in hST-3-transfected MCF-7 cells. Such proteolysis may thus play a role in in vivo tumor progression. These results indicate that hST-3 may regulate IGF-I bioavailability by proteolyzing IGFBP, thus favoring cell survival and proliferation.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, CSIC, Universidad Autonoma de Madrid, Campus de Cantoblanco, E-28049 Madrid, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Mañes S, Kremer L, Vangbo B, López A, Gómez-Mouton C, Peiró E, Albar JP, Mendel-Hartvig IB, Llopis R, Martínez C. Physical mapping of human insulin-like growth factor-I using specific monoclonal antibodies. J Endocrinol 1997; 154:293-302. [PMID: 9291840 DOI: 10.1677/joe.0.1540293] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The primary structure of recombinant human (h) insulin-like growth factor-I (IGF-I) epitopes recognized by a panel of 28 monoclonal antibodies (mAbs) is characterized. Pairwise mAb epitope mapping defines eight 'epitopic clusters' (I-VIII) which cover nearly the entire solvent-exposed IGF-I surface. Monoclonal antibody reactivity with 32 overlapping synthetic peptides and with IGF-I mutants is used to associate these epitopic clusters with the probable primary IGF-I sequences recognized. Epitopic cluster I involves residues in the C-domain and the first alpha-helix of the A-domain; clusters II, V and VII involve principally the B-domain; clusters III and IV map to amino acid sequences (55-70) and (1-13) respectively; cluster VI includes the A- and B-domains; and cluster VIII involves mainly the C-terminal part of the B-domain. Data indicate that this mAb panel defines 14 distinct IGF-I epitopes. The specific inhibition of HEL 92.1.7 IGF-I-promoted proliferation by these mAbs was explored. Direct correlation between mAb affinity and inhibitory activity was observed except in the case of clusters III- and VIII-specific mAbs. Finally, the combination of epitopic cluster I and II mAbs detect 0.5-10 ng/ml hIGF-I in a sandwich immunoassay, with no IGF-II crossreactivity. These anti-IGF-I mAbs are, therefore, useful for both the inhibition of IGF-I mitogenic activity and for the quantification of this growth factor. The potential use of this mAb panel in tumor cell growth control is discussed.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, CSIC, Universidad Autonoma de Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Mañes S, Kremer L, Albar JP, Mark C, Llopis R, Martínez C. Functional epitope mapping of insulin-like growth factor I (IGF-I) by anti-IGF-I monoclonal antibodies. Endocrinology 1997; 138:905-15. [PMID: 9048589 DOI: 10.1210/endo.138.3.4965] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Based on a collection of monoclonal antibodies (mAb) against insulin-like growth factor I (IGF-I), we have defined the IGF-I epitopes involved in the interaction with IGF-binding proteins (IGFBP) and IGF-I receptors. We have also characterized the ability of these antibodies to block IGF-I-induced survival of the IL-3-dependent Ba/F3 cell line. More than 140 hybridomas secreting IGF-I-specific mAb were characterized, of which 28 were studied in detail. They display apparent affinity constants ranging from less than 10(6) to 10(10) M-1 and varying crossreactivity with IGF-II, including 2 mAb with higher affinity for IGF-II than for IGF-I. None crossreact with insulin or any other growth factor tested. Using both enzyme immunoassays and real-time biospecific interaction analysis, we have identified 8 epitopic clusters related to the primary structure of IGF-I, according to mAb reactivity to synthetic peptides, proteolytic fragments of IGF-I, and various IGF-I mutants. The mAb panel also was used to map the IGF domains implicated in the interaction with IGFBP and IGF-I receptors. An IGF-I domain has been identified that remains exposed after IGF-I binding to IGFBP-1 or to IGFBP-3, which is recognized by 6 different mAb. The mAb in this group also bind IGF-I, when complexed to the type-1 IGF receptor on the murine pro-B cell line Ba/F3, and BALB/c 3T3 fibroblasts overexpressing the human receptor. Finally, IGF-I-promoted survival can be blocked with mAb specific for target epitopes, and their potential use in tumor cell growth control is discussed.
Collapse
Affiliation(s)
- S Mañes
- Department of Immunology and Oncology, Universidad Autonoma de Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
20
|
Esteva M, Mañes S, del Palacio MA, López-Sebastián A. [Effect of ovariectomy on plasma levels of progesterone, free and conjugated estrone in pregnant sheep]. Rev Esp Fisiol 1988; 44:197-203. [PMID: 3194577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Progesterone, free and conjugated estrone were determined in peripheral plasma from ovariectomized and control pregnant ewes in order to observe the ovary contribution to these hormonal levels. Progesterone levels during pregnancy were lower in the ovariectomized ewes than in control, although the differences were significant only until the 120th day of pregnancy. From the 130th day to the 3rd-5th day prepartum, an increase in the hormone levels was observed in both groups of ewes indicating a placentary contribution. Very similar patterns were followed by the free and conjugated estrone concentrations, their levels not being significantly different in either group. Production of conjugated estrone both preceded and reached higher values than that of free estrone. Both hormones showed an abrupt increase in concentration two days before the parturition, decreasing after that. Parturition mechanisms, foetus viability and the length of pregnancy were not affected by ovariectomy.
Collapse
Affiliation(s)
- M Esteva
- Departamento de Reproducción Animal, C.I.T.-I.N.I.A., Madrid, España
| | | | | | | |
Collapse
|